Literature DB >> 9360531

Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma.

C K Welt1, G Lambert-Messerlian, W Zheng, W F Crowley, A L Schneyer.   

Abstract

Activin induces proliferation in epithelial ovarian carcinoma cell lines, whereas follistatin (FS), an activin binding protein, inhibits this action. To test the hypothesis that activin production, in excess of inhibin and FS, results in cell proliferation in epithelial ovarian tumors, messenger RNA (mRNA) expression of the activin family of proteins, FS, and activin type I and II receptors was examined in 25 primary epithelial ovarian tumors and tumor epithelium in culture (n = 7) using RT-PCR. Activin A was measured in the serum of ovarian cancer patients, and activin A, total inhibin, and FS protein secretion was measured from primary epithelial tumors in vitro. The effect of activin and FS on cell proliferation was assessed by measuring [3H]thymidine incorporation. All results were compared with normal ovarian epithelium. All epithelial ovarian tumors expressed mRNA for the alpha, beta A, and beta B subunits; FS 288 and 315; and the activin type IA, IB, II, and IIB receptors. beta A mRNA expression, as assessed using semiquantitative RT-PCR, was 3-fold greater in cultured tumor epithelium than in primary tumors (band density 0.86 +/- 0.17 vs. 0.28 +/- 0.09; P < 0.01). In addition, beta A mRNA was abundantly expressed in normal epithelium in culture (n = 2), whereas only trace amounts were seen in 2/9 primary epithelial samples. Activin protein was secreted by 24/25 primary epithelial ovarian tumors (range 0.2-155.8 ng/mL). In contrast, total inhibin was secreted by only 2/25 (range 0.01-0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (< 0.5 ng/mL). Treatment with activin or FS did not consistently affect cell growth. Measurement of serum activin A in a subset of subjects and in 27 additional subjects with epithelial ovarian carcinoma (n = 33) revealed preoperative activin A levels > 3 SD above the mean for pre- and postmenopausal women in 13/33 (39%) subjects. We conclude that in epithelial ovarian cancer: 1) beta A subunit mRNA is expressed, 2) activin protein is secreted more frequently than inhibin and in greater quantities than FS, 3) beta A subunit mRNA expression is greater in neoplastic and normal epithelium in culture than in the primary tissue, 4) the majority of tumors in culture do not respond to activin or FS treatment with proliferation, and 5) serum activin levels may reflect tumor secretion in some patients. Thus, activin A appears to be available as an autocrine/paracrine factor in epithelial ovarian tumors and may contribute to circulating levels, but its role in tumorigenesis has yet to be defined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360531     DOI: 10.1210/jcem.82.11.4345

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.

Authors:  Jessica J Tao; Nicholas A Cangemi; Vicky Makker; Karen A Cadoo; Joyce F Liu; Drew W Rasco; Willis H Navarro; Christopher M Haqq; David M Hyman
Journal:  Clin Cancer Res       Date:  2019-05-08       Impact factor: 12.531

2.  Establishment and characterization of a human ovarian granulosa tumor cell line (HSOGT).

Authors:  Haruhiro Kondo; Kazushige Kiguchi; Asami Okamura; Yoshiaki Okuma; Tomohiro Iida; Yoichi Kobayashi; Masayuki Takagi; Bunpei Ishizuka; Isamu Ishiwata
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

3.  BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.

Authors:  Tejaswita M Karve; Anju Preet; Rosie Sneed; Clara Salamanca; Xin Li; Jingwen Xu; Deepak Kumar; Eliot M Rosen; Tapas Saha
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

Review 4.  Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.

Authors:  Maria V Barbolina; Rebecca J Burkhalter; M Sharon Stack
Journal:  Biochem J       Date:  2011-07-01       Impact factor: 3.857

5.  Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma.

Authors:  I Ito; T Minegishi; J Fukuda; H Shinozaki; N Auersperg; P C Leung
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

6.  Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.

Authors:  Agnieszka Horala; Agata Swiatly; Jan Matysiak; Paulina Banach; Ewa Nowak-Markwitz; Zenon J Kokot
Journal:  Int J Mol Sci       Date:  2017-01-10       Impact factor: 5.923

7.  Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.

Authors:  Xiaoting Li; Zongyuan Yang; Sen Xu; Zhengzheng Wang; Ping Jin; Xin Yang; Zeyu Zhang; Ya Wang; Xiao Wei; Tian Fang; Qinglei Gao
Journal:  Dis Markers       Date:  2019-11-11       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.